These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26342928)

  • 21. How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?
    Mulhern B; Norman R; Shah K; Bansback N; Longworth L; Viney R
    Med Decis Making; 2018 Apr; 38(3):306-318. PubMed ID: 29084472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The European Organisation for Research and Treatment of Cancer Quality of Life Utility-Core 10 Dimensions: Development and Investigation of General Population Utility Norms for Canada, France, Germany, Italy, Poland, and the United Kingdom.
    Pilz MJ; Nolte S; Liegl G; King M; Norman R; McTaggart-Cowan H; Bottomley A; Rose M; Kemmler G; Holzner B; Gamper EM;
    Value Health; 2023 May; 26(5):760-767. PubMed ID: 36572102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health state utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS Preference Score.
    Klapproth CP; Fischer F; Rose M; Karsten MM
    J Clin Epidemiol; 2022 Dec; 152():101-109. PubMed ID: 36162712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.
    Gamper EM; Cottone F; Sommer K; Norman R; King M; Breccia M; Caocci G; Patriarca A; Palumbo GA; Stauder R; Niscola P; Platzbecker U; Caers J; Vignetti M; Efficace F
    J Clin Epidemiol; 2021 Sep; 137():31-44. PubMed ID: 33753228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states.
    Norman R; Cronin P; Viney R
    Appl Health Econ Health Policy; 2013 Jun; 11(3):287-98. PubMed ID: 23649892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.
    Pilz MJ; Seyringer S; Al-Naesan I; King MT; Bottomley A; Norman R; Schlosser L; Hell T; Gamper EM;
    Pharmacoecon Open; 2024 Jul; 8(4):627-640. PubMed ID: 38696019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of Health-Related Utilities for
    Soare IA; Leeuwenkamp O; Longworth L
    Pharmacoecon Open; 2021 Dec; 5(4):715-725. PubMed ID: 34260017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set.
    King MT; Norman R; Mercieca-Bebber R; Costa DSJ; McTaggart-Cowan H; Peacock S; Janda M; Müller F; Viney R; Pickard AS; Cella D;
    Value Health; 2021 Jun; 24(6):862-873. PubMed ID: 34119085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Preferences and Data Quality between Discrete Choice Experiments Conducted in Online and Face-to-Face Respondents.
    Jiang R; Pullenayegum E; Shaw JW; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
    Med Decis Making; 2023 Aug; 43(6):667-679. PubMed ID: 37199407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigating the relative value of health and social care related quality of life using a discrete choice experiment.
    Mulhern B; Norman R; De Abreu Lourenco R; Malley J; Street D; Viney R
    Soc Sci Med; 2019 Jul; 233():28-37. PubMed ID: 31153085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments.
    Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA
    Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whose Time Trade-Off Should Be Used? Anchoring Discrete Choice Experiment Latent Utilities in Health State Valuation.
    Xie S; Wu J; Xie F
    Value Health; 2023 Sep; 26(9):1405-1412. PubMed ID: 37285916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
    Kim H; Cook G; Goodall S; Liew D
    Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
    Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
    Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Australian Public Preferences for the Funding of New Health Technologies: A Comparison of Discrete Choice and Profile Case Best-Worst Scaling Methods.
    Whitty JA; Ratcliffe J; Chen G; Scuffham PA
    Med Decis Making; 2014 Jul; 34(5):638-54. PubMed ID: 24713695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Not all respondents use a multiplicative utility function in choice experiments for health state valuations, which should be reflected in the elicitation format (or statistical analysis).
    Jonker MF; Norman R
    Health Econ; 2022 Feb; 31(2):431-439. PubMed ID: 34841637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.
    Pilz MJ; Seyringer S; Hallsson LR; Bottomley A; Jansen F; King MT; Norman R; Rutten MJ; Verdonck-de Leeuw IM; Siersema PD; Gamper EM
    Eur J Health Econ; 2024 Mar; ():. PubMed ID: 38483665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health utility assessments in individuals undergoing diagnostic and surveillance colonoscopy: improved discrimination with a cancer-specific scale.
    Bulamu NB; Chen G; McGrane E; Cock C; Young GP; Symonds EL
    Cancer Causes Control; 2024 Feb; 35(2):347-357. PubMed ID: 37747615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing an Australian utility value set for MacNew-7D health states.
    Kularatna S; Chen G; Norman R; Mukuria C; Rowen D; Senanayake S; Hettiarachchi R; Mulhern B; Fozzard K; Parsonage W; MacPhail SM
    Qual Life Res; 2023 Apr; 32(4):1151-1163. PubMed ID: 36542299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument.
    King MT; Revicki DA; Norman R; Müller F; Viney RC; Pickard AS; Cella D; Shaw JW;
    Pharmacoecon Open; 2024 Jan; 8(1):49-63. PubMed ID: 38060096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.